Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ACTRN12626000242325) titled 'A single ascending dose study of TX002100 in healthy participants' on Feb. 26.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Type of endpoint: Safety
Primary Sponsor: Tectonic Operating Company. Inc.
Condition:
Hereditary hemorrhagic telangiectasia
Hereditary hemorrhagic telangiectasia
Blood - Haematological diseases
Intervention:
TX002100 is an Fc-fusion protein.
Investigational product: TX002100 or Matching placebo. Approximately 48 participants will be enrolled in this study. Single dose of TX0...